<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989079</url>
  </required_header>
  <id_info>
    <org_study_id>8835-036</org_study_id>
    <nct_id>NCT00989079</nct_id>
  </id_info>
  <brief_title>A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)</brief_title>
  <official_title>A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of PF-04971729 After Administration of Single Escalating Oral Doses Under Fed and Fasted Conditions in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2
      diabetes mellitus. The primary purpose of this study is to evaluate the safety and
      tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin
      under fed and fasted conditions in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to Day 10 of each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Up to Day 8 of each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in 24-hour urinary glucose excretion</measure>
    <time_frame>Baseline and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from Time 0 to infinity (AUCinf) for ertugliflozin</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from Time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ertugliflozin</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ertugliflozin half life (t1/2)</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) after a single dose of ertugliflozin</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose excretion over 72 hours</measure>
    <time_frame>Up to 72 hours of each dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour weighted mean glucose</measure>
    <time_frame>Baseline and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of glucose reabsorption</measure>
    <time_frame>Up to 24 hours of each dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr) of Ertugliflozin</measure>
    <time_frame>Up to 24 hours of each dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary recovery of Ertugliflozin</measure>
    <time_frame>Up to 24 hours of each dosing period</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.</description>
    <arm_group_label>Cohort 1 Sequence 1</arm_group_label>
    <arm_group_label>Cohort 1 Sequence 2</arm_group_label>
    <arm_group_label>Cohort 1 Sequence 3</arm_group_label>
    <arm_group_label>Cohort 2 Sequence 1</arm_group_label>
    <arm_group_label>Cohort 2 Sequence 2</arm_group_label>
    <arm_group_label>Cohort 2 Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertugliflozin</intervention_name>
    <description>Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution</description>
    <arm_group_label>Cohort 1 Sequence 1</arm_group_label>
    <arm_group_label>Cohort 1 Sequence 2</arm_group_label>
    <arm_group_label>Cohort 1 Sequence 3</arm_group_label>
    <arm_group_label>Cohort 2 Sequence 1</arm_group_label>
    <arm_group_label>Cohort 2 Sequence 2</arm_group_label>
    <arm_group_label>Cohort 2 Sequence 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects of non childbearing potential.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single Ascending Dose Study in healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

